Pathogenesis and Treatment of Amyotrophic Lateral Sclerosis (ALS)

Dear Colleagues,

This Special Issue provides a comprehensive platform for advancing the understanding of amyotrophic lateral sclerosis (ALS) pathogenesis and accelerating the development of effective treatments. As a multifactorial neurodegenerative disease, ALS involves complex interactions between genetic susceptibility, molecular pathways, and cellular processes. We welcome original contributions that explore multi-target therapeutic strategies, including novel drug development and rational combination therapies designed to address the disease's heterogeneity. Submissions utilizing cutting-edge methodologies—such as artificial intelligence-based prediction models, multi-omics data integration, and patient-derived iPSC platforms—for target discovery, drug repurposing use, and patient stratification are particularly encouraged. The issue also seeks innovative clinical trial designs incorporating adaptive protocols, novel endpoint selection, and biomarker-guided strategies to enhance trial efficiency and accuracy. We invite research on diverse intervention modalities ranging from pharmacological approaches (including small molecules, gene therapies, cell-based treatments, and traditional medicines) to non-pharmacological interventions such as neuromodulation and rehabilitation strategies. A key emphasis is placed on translational research that successfully bridges mechanistic insights from basic science with practical clinical applications, ultimately aiming to delay disease progression, extend survival, and improve patients' symptoms and quality of life. The Special Issue invites both original research articles and comprehensive review papers that address these critical areas in ALS research.

Prof. Dr. Dongsheng Fan
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.